LAB · CIK 0001162194 · operating
Standard BioTools develops and sells laboratory instrumentation, consumables, and software for protein and gene analysis across research and clinical settings. The company operates two primary segments: Proteomics and Genomics. Its proteomics offerings include the SomaScan platform for simultaneous protein measurement, the CyTOF technology platform utilizing metal-tagged antibodies and time-of-flight mass spectrometry, and Hyperion, a spatial biology platform that preserves tissue context during molecular analysis. In genomics, the company provides the Biomark X9 system for high-throughput quantitative polymerase chain reaction applications.
The company sells research-use-only instruments and consumables to academic research institutions, translational research centers, cancer centers, and clinical research laboratories, as well as to biopharmaceutical, biotechnology, and agricultural research companies. Standard BioTools maintains technology license agreements with institutions including the California Institute of Technology and Harvard University.
Headquartered in South San Francisco, California, the company operates across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company was incorporated in 1999 and rebranded from Fluidigm Corporation to Standard BioTools in April 2022. It is listed on Nasdaq with a market capitalization of approximately $0.4 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.52 | $-0.52 | +44.7% | |
| 2023 | $-0.94 | $-0.94 | +61.3% | |
| 2022 | $-2.43 | $-2.43 | -211.5% | |
| 2021 | $-0.78 | $-0.78 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-11 | 0000950170-25-036608 | SEC ↗ |
| 2023-12-31 | 2024-03-01 | 0000950170-24-023845 | SEC ↗ |
| 2022-12-31 | 2023-03-14 | 0001162194-23-000013 | SEC ↗ |
| 2021-12-31 | 2022-03-08 | 0001162194-22-000021 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001162194-21-000013 | SEC ↗ |
| 2019-12-31 | 2020-02-27 | 0001162194-20-000016 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001162194-19-000020 | SEC ↗ |
| 2017-12-31 | 2018-03-08 | 0001162194-18-000032 | SEC ↗ |
| 2016-12-31 | 2017-03-03 | 0001628280-17-002137 | SEC ↗ |
| 2015-12-31 | 2016-02-29 | 0001162194-16-000182 | SEC ↗ |